Safety and efficacy of natalizumab in children with multiple sclerosis
Neurology, ISSN: 0028-3878, Vol: 75, Issue: 10, Page: 912-917
2010
- 89Citations
- 82Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations89
- Citation Indexes86
- 86
- CrossRef73
- Policy Citations2
- Policy Citation2
- Clinical Citations1
- PubMed Guidelines1
- Captures82
- Readers82
- 82
- Mentions1
- Blog Mentions1
- Blog1
Most Recent Blog
Tysabri vermindert invaliditeit bij kinderen
Uit een Italiaans onderzoek is gebleken dat jongeren met een actieve vorm van MS het medicijn Tysabri goed verdragen. Het onderdrukte bij hen de ontwikkeling van de ziekte gedurende een gemiddelde periode van ruim een jaar. Zij kregen in dat jaar elke vier weken een infuus met daarin 300 mgr Tysabri. Hun invaliditeit nam af. Italiaanse onderzoekers uit Galalrate in Italië hebben het effect ond
Article Description
To describe the effect of natalizumab in the treatment of subjects with active multiple sclerosis (MS) treated before the age of 18 years.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0028387810609144; http://dx.doi.org/10.1212/wnl.0b013e3181f11daf; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77957047229&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/20820002; https://www.neurology.org/doi/10.1212/WNL.0b013e3181f11daf; https://dx.doi.org/10.1212/wnl.0b013e3181f11daf; https://n.neurology.org/content/75/10/912
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know